Blood test predicts which patients with lung cancer will benefit from newly approved immunotherapy drug
Peer-Reviewed Publication
Updates every hour. Last Updated: 16-Jan-2026 22:11 ET (17-Jan-2026 03:11 GMT/UTC)
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab. The findings, which are published in Cancer Discovery, could allow clinicians to easily and noninvasively determine which patients should receive the drug.
A toxin secreted by cholera bacteria can inhibit the growth of colorectal cancer without causing any measurable damage to the body. This is shown by a new study by researchers at Umeå University, Sweden. Systemic administration of the purified bacterial substance changes the immune microenvironment in tumours, and the results may open the way for research into a new type of cancer treatment.
In a new study, researchers from France have revealed why people with neurofibromatosis type 1 (NF1) often develop serious spine problems, such as scoliosis. Their findings show that faulty bone-forming cells cause the spine to grow abnormally over time. In mice, drugs that blocked an overactive cell signaling pathway were able to stop these spine deformations, suggesting that existing medicines could one day help prevent spinal deformities in people with NF1.
Large language models (LLM) can generate treatment recommendations for straightforward cases of hepatocellular carcinoma (HCC) that align with clinical guidelines but fall short in more complex cases, according to a new study by Ji Won Han from The Catholic University of Korea and colleagues publishing January 13th in the open-access journal PLOS Medicine.
Deep learning model trained with stage II colorectal cancer whole slide images identifies features associated with risk of recurrence – with higher success rate than clinical prognostic parameters